Abstract
Depression is a common co-morbidity in patients with cardiovascular diseases such as chronic coronary artery disease, acute coronary syndromes, post by-pass surgery and chronic heart failure. The presence of depression is independently associated with a decline in health status and an increase in the risk of hospitalization and death for patients with coronary artery disease or congestive heart failure. Novel treatment modalities such as selective serotonin re-uptake inhibitors (SSRIs) may improve depressive symptoms and prognosis of post-myocardial infarction and heart failure patients interacting with the common pathophysiological mechanisms of depression and cardiovascular disease. This review summarizes current experimental and clinical evidence regarding the effects of SSRIs on platelet functions, immune and neurohormonal activation, and cardiac rhythm disturbances in patients with cardiovascular disease.
Keywords: Cardiovascular disease, chronic heart failure, citalopram, coronary artery disease, dapoxetine, depression, escitalopram, fluoxetine, fluvoxamin, paroxetine, selective serotonin re-uptake inhibitors, sertraline, vilazodone
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Treating Depression in Coronary Artery Disease and Chronic Heart Failure: What’s new in using Selective Serotonin Re-Uptake Inhibitors?
Volume: 10 Issue: 2
Author(s): Paraskevaidis Ioannis, Palios John, Parissis John, Filippatos Gerasimos and Anastasiou-Nana Maria
Affiliation:
Keywords: Cardiovascular disease, chronic heart failure, citalopram, coronary artery disease, dapoxetine, depression, escitalopram, fluoxetine, fluvoxamin, paroxetine, selective serotonin re-uptake inhibitors, sertraline, vilazodone
Abstract: Depression is a common co-morbidity in patients with cardiovascular diseases such as chronic coronary artery disease, acute coronary syndromes, post by-pass surgery and chronic heart failure. The presence of depression is independently associated with a decline in health status and an increase in the risk of hospitalization and death for patients with coronary artery disease or congestive heart failure. Novel treatment modalities such as selective serotonin re-uptake inhibitors (SSRIs) may improve depressive symptoms and prognosis of post-myocardial infarction and heart failure patients interacting with the common pathophysiological mechanisms of depression and cardiovascular disease. This review summarizes current experimental and clinical evidence regarding the effects of SSRIs on platelet functions, immune and neurohormonal activation, and cardiac rhythm disturbances in patients with cardiovascular disease.
Export Options
About this article
Cite this article as:
Ioannis Paraskevaidis, John Palios, John Parissis, Gerasimos Filippatos and Maria Anastasiou-Nana, Treating Depression in Coronary Artery Disease and Chronic Heart Failure: What’s new in using Selective Serotonin Re-Uptake Inhibitors?, Cardiovascular & Hematological Agents in Medicinal Chemistry 2012; 10 (2) . https://dx.doi.org/10.2174/187152512800388894
DOI https://dx.doi.org/10.2174/187152512800388894 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Use of Medications for the Treatment of Alcohol Dependence: A Retrospective Study Conducted in 2011-2012
Current Drug Research Reviews Selection of Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention
Current Pharmaceutical Design The Design of Drug Candidate Molecules as Selective Inhibitors of Therapeutically Relevant Protein Kinases
Current Medicinal Chemistry Epidemiology and Risk Factors of Cerebral Ischemia and Ischemic Heart Diseases: Similarities and Differences
Current Cardiology Reviews Long-term Etanercept Therapy Favors Weight Gain and Ameliorates Cachexia in Rheumatoid Arthritis Patients: Roles of Gut Hormones and Leptin
Current Pharmaceutical Design Targeting Cardiomyocyte Ca<sup>2+</sup> Homeostasis in Heart Failure
Current Pharmaceutical Design Preface [Hot Topic: Signal Transduction Therapy: Facts and Visions Executive Editor: Claus Liebmann ]
Current Pharmaceutical Design Effect of Rehabilitative Exercise Training on Peripheral Muscle Remodelling in Patients with COPD: Targeting Beyond the Lungs
Current Drug Targets Safety of Dabigatran in an Elderly Population: Single Center Experience in Italy
Current Drug Safety Current Insights into the Role of HIF-1 in Cutaneous Wound Healing
Current Molecular Medicine Inhibitory Smad7: Emerging Roles in Health and Disease
Current Molecular Pharmacology Sodium-Proton Exchanger Isoform-1: Synthesis of a Potent Inhibitor Labeled with Deuterium and Carbon-14
Current Radiopharmaceuticals Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis
Recent Patents on Biomedical Engineering (Discontinued) Pulmonary Hypertension and Systemic Diseases
Current Drug Targets - Inflammation & Allergy New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is)
Current Medicinal Chemistry MicroRNA Therapeutics: the Next Magic Bullet?
Mini-Reviews in Medicinal Chemistry Cardioprotective Potential of Iron Chelators and Prochelators
Current Medicinal Chemistry Nanocrystalline ZnO: A Competent and Reusable Catalyst for the Preparation of Pharmacology Relevant Heterocycles in the Aqueous Medium
Current Green Chemistry Cell Surface Nucleolin as a Target for Anti-Cancer Therapies
Recent Patents on Anti-Cancer Drug Discovery Human Embryonic and Induced Pluripotent Stem Cells in Cardiovascular Drug Discovery: Patents and Patented Uses
Recent Patents on Cardiovascular Drug Discovery